WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413043
CAS#: 1931994-81-8
Description: Zabedosertib, also known as BAY 1834845, is a IRAK-4 inhibitor. IRAK-4 inhibitors are an exciting therapeutic option in RA management because unlike other targeted disease-modifying agents, they target the innate immune system. The role of IRAK-4 as a key component of Toll/Interleukin-1 receptor signaling and its potential for a low rate of infectious complications is particularly exciting and this may facilitate their use in combination treatment.
Hodoodo Cat#: H413043
Name: Zabedosertib
CAS#: 1931994-81-8
Chemical Formula: C20H21F3N4O4S
Exact Mass: 470.12
Molecular Weight: 470.470
Elemental Analysis: C, 51.06; H, 4.50; F, 12.11; N, 11.91; O, 13.60; S, 6.81
Synonym: Zabedosertib; BAY 1834845; BAY1834845; BAY-1834845;
IUPAC/Chemical Name: N-{6-(2-hydroxypropan-2-yl)-2-[2-(methanesulfonyl)ethyl]- 2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2- carboxamide
InChi Key: OQAMEEFUUFJZRS-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H21F3N4O4S/c1-19(2,29)13-10-15-12(11-27(26-15)7-8-32(3,30)31)9-16(13)25-18(28)14-5-4-6-17(24-14)20(21,22)23/h4-6,9-11,29H,7-8H2,1-3H3,(H,25,28)
SMILES Code: O=C(C1=NC(C(F)(F)F)=CC=C1)NC2=CC3=CN(CCS(=O)(C)=O)N=C3C=C2C(C)(O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity. Despite current treatment modalities, many patients are still unable to reach remission. Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are novel agents designed to suppress immune signaling pathways involved in inflammation and joint destruction in RA. Four IRAK-4 inhibitors have entered clinical trials.
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 470.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
